Clinical trial · Interventional
Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML.
Azacytidine-venetoclax Combination as Leukemia Debulking Treatment Followed by Reduced Toxicity Conditioning Regimen (Melphalan Busulfan and Fludarabine, MBF) as Salvage Therapy for Refractory Acute Myeloid Leukemia (AML).
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this phase clinical trail, we evaluate the efficacy and feasibility of azacytidine and venetoclax as leukemia debulking treatment followed by reduced intensity conditioning regimen consisting of Fludarabine + Busulfan + Melphalan as salvage treatment in patients with refractory AML .
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Aza-Ven-allo-HSCT | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- aza-ven +MBF
- description
- treatment with aza-ven debulking therapy followed by allo-HSCT with MBF conditioning
- interventionNames
- Drug: Aza-Ven-allo-HSCT
Primary outcomes (1)
- measure
- relapse-free survival
- timeFrame
- 12 months
- description
- event defined as relapse or death of any causes
Secondary outcomes (4)
- measure
- overall survival
- timeFrame
- 12 months
- description
- event defined as death of all causes
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * refractory AML (no remission after 2 induction therapy, relapsed AML within 6 months of first complete remission (CR), relapse AML no CR after reinduction therapy), multiple relapse and refractory relapse AML * patients with HLA matched related or unrelated donor (9\~10/10) or haplo-identical related donor Exclusion Criteria: * Patients with poor liver function (enzyme \>2N or bilirubin \>2N) * poor renal function (Scr \>1.5N) * poor cardiac function （EF\<45%） * inform consent not provided
References
Publications (0)
Data not yet available